Cargando…
Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review
Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046337/ https://www.ncbi.nlm.nih.gov/pubmed/36979900 http://dx.doi.org/10.3390/biomedicines11030921 |
_version_ | 1785013647656878080 |
---|---|
author | Brasso, Claudio Colli, Gianluca Sgro, Rodolfo Bellino, Silvio Bozzatello, Paola Montemagni, Cristiana Villari, Vincenzo Rocca, Paola |
author_facet | Brasso, Claudio Colli, Gianluca Sgro, Rodolfo Bellino, Silvio Bozzatello, Paola Montemagni, Cristiana Villari, Vincenzo Rocca, Paola |
author_sort | Brasso, Claudio |
collection | PubMed |
description | Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research. We searched the PubMed database for original studies using SDAM, aripiprazole, cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective than placebo in reducing NS. Only six studies compared SDAMs with other classes of antipsychotics, demonstrating a superiority in the treatment of NS mainly for cariprazine. The lack of specific research and various methodological issues, related to the study population and the assessment of NS, may have led to these partial results. Here, we highlight the need to conduct new methodologically robust investigations with head-to-head treatment comparisons and long-term observational studies on homogeneous groups of patients evaluating persistent NS with first- and second-generation scales, namely the Brief Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms. This rapid review can expand research on NS therapeutic strategies in schizophrenia, which is fundamental for the long-term improvement of patients’ quality of life. |
format | Online Article Text |
id | pubmed-10046337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100463372023-03-29 Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review Brasso, Claudio Colli, Gianluca Sgro, Rodolfo Bellino, Silvio Bozzatello, Paola Montemagni, Cristiana Villari, Vincenzo Rocca, Paola Biomedicines Review Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research. We searched the PubMed database for original studies using SDAM, aripiprazole, cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective than placebo in reducing NS. Only six studies compared SDAMs with other classes of antipsychotics, demonstrating a superiority in the treatment of NS mainly for cariprazine. The lack of specific research and various methodological issues, related to the study population and the assessment of NS, may have led to these partial results. Here, we highlight the need to conduct new methodologically robust investigations with head-to-head treatment comparisons and long-term observational studies on homogeneous groups of patients evaluating persistent NS with first- and second-generation scales, namely the Brief Negative Symptom Scale and the Clinical Assessment Interview for Negative Symptoms. This rapid review can expand research on NS therapeutic strategies in schizophrenia, which is fundamental for the long-term improvement of patients’ quality of life. MDPI 2023-03-16 /pmc/articles/PMC10046337/ /pubmed/36979900 http://dx.doi.org/10.3390/biomedicines11030921 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Brasso, Claudio Colli, Gianluca Sgro, Rodolfo Bellino, Silvio Bozzatello, Paola Montemagni, Cristiana Villari, Vincenzo Rocca, Paola Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review |
title | Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review |
title_full | Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review |
title_fullStr | Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review |
title_full_unstemmed | Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review |
title_short | Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review |
title_sort | efficacy of serotonin and dopamine activity modulators in the treatment of negative symptoms in schizophrenia: a rapid review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046337/ https://www.ncbi.nlm.nih.gov/pubmed/36979900 http://dx.doi.org/10.3390/biomedicines11030921 |
work_keys_str_mv | AT brassoclaudio efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT colligianluca efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT sgrorodolfo efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT bellinosilvio efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT bozzatellopaola efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT montemagnicristiana efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT villarivincenzo efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview AT roccapaola efficacyofserotoninanddopamineactivitymodulatorsinthetreatmentofnegativesymptomsinschizophreniaarapidreview |